NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital leads $67.5 million (€64.4 million) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease
Proceeds of financing will support two double-blinded Phase 2 trials for its lead candidate XC001, a pioneering transformative gene therapy approach for the treatment of severe cardiovascular disease. This investment builds on Jeito's expertise in cardiology,...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Jeito Capital announces acquisition of portfolio company HI-Bio™ by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 billion; Biogen to strengthen portfolio to help patients with severe immune-mediated disease
Biogen Inc. (Nasdaq: BIIB) to acquire HI-Bio™ for a total consideration of up to $1.8 billion...
Jeito Capital strengthens its Executive Committee with the appointment of Sarah Leroy who is taking the newly created position of Secretary General responsible for managing Legal and Financial Affairs, Compliance, HR and Sustainability
Paris, France, March 14th 2024 - Jeito Capital ("Jeito"), a global leading independent private...
EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting
Twelve week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients...
Jeito Capital participates in a $95 Million financing for HI-Bio™, a US-based clinical-stage biopharma company developing targeted therapies for patients with severe immune-mediated diseases
One year after its first investment, this new significant participation in HI-Bio™’s Series B...
Jeito Capital portfolio company Advesya emerges from stealth mode with the potential to become a leader in the treatment of hematological malignancies and other tumor treatments
Paris, France, 3 January 2024 - Jeito Capital ("Jeito"), a global leading independent private...
Jeito Capital announces appointment of new Partner Investor Ksenija Pavletic
Paris, France, 3 January 2024 - Jeito Capital ("Jeito"), a global leading independent private...
Face to face
Meet Jeito
16-17
December
All day long
Conference of Paris 2024
Jeito will be present at the Conference of Paris 2024, for its 8th edition around the theme “Confronting the Unknown”, encouraging leaders to share their knowledge and understanding of global economic, social and environmental issues as a way to collaborate and collectively overcome these challenges.
13-16
January
All day long
JPM Healthcare Conference 2025
Jeito will be present at the 43rd JPM Healthcare Conference 2025, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.
28-30
January
All day long
IPEM Cannes 2025
Jeito will be present at the 11th edition of IPEM Cannes – Wealth 2025, gathering Private Capital key decision-makers and incubating this year “IPEM Wealth”, a brand-new format designed to support the democratization of Private Markets, in Cannes.